Exercise of Warrants; Total Voting Rights

RNS Number : 3856Y
Integumen PLC
08 September 2020
 

 

AIM share code: SKIN

08 September 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

 

Exercise of Warrants  

 

Integumen announces that it has received notification from a warrant holder to exercise warrants over 500,000 shares in the share capital of Integumen ("the Warrant Shares") at an exercise price of 2 pence. T he consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £10,000 .

 

Total voting rights

 

The Warrant Shares were allotted on 08 September 2020. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or about 14 September 2020. These shares will rank pari passu with the ordinary shares of the Company in issue.

 

The Company's total issued share capital, following the issue of the Warrant Shares, will be 1,127,013,569 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 

 

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648




SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974




Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050




 

About Integumen plc:

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVEALITIII
UK 100

Latest directors dealings